Open access · US-GOV via ClinicalTrials.gov Clinical trial

A Principal, Open-Label, Single Center Study to Validate the Detection of Cerebral Cortical Amyloid With Flutemetamol (18F) Injection in Subjects Previously Biopsied

Authors not listed

GE Healthcare · 2009

Dysbiosis Human Randomized controlled trial

Abstract

This study will determine the level of association between the quantitative estimates of brain uptake of \[18F\]flutemetamol and the quantitative immunohistochemical estimates of amyloid levels in biopsy samples previously obtained during shunt placement in patients who have normal pressure hydrocephalus (NPH).

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source: ClinicalTrials.gov
Canonical: link ↗
Fetched: 2026-10-26 MST

Cite this

APA

Anonymous. (2009). A Principal, Open-Label, Single Center Study to Validate the Detection of Cerebral Cortical Amyloid With Flutemetamol (18F) Injection in Subjects Previously Biopsied. <em>GE Healthcare</em>. https://clinicaltrials.gov/study/NCT01053312

Vancouver

Anonymous. A Principal, Open-Label, Single Center Study to Validate the Detection of Cerebral Cortical Amyloid With Flutemetamol (18F) Injection in Subjects Previously Biopsied. GE Healthcare. 2009.

BibTeX

@misc{anon2009APrinc, title = {A Principal, Open-Label, Single Center Study to Validate the Detection of Cerebral Cortical Amyloid With Flutemetamol (18F) Injection in Subjects Previously Biopsied}, author = {Anonymous}, journal = {GE Healthcare}, year = {2009}, }